<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Celivarone is a new antiarrhythmic agent developed for the treatment of <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated the efficacy and safety of celivarone in preventing implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) interventions or <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Celivarone (50, 100, or 300 mg/d) was assessed compared with placebo in this randomized, double-blind, placebo-controlled, parallel-group study </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="2663">Amiodarone</z:chebi> (200 mg/d after loading dose of 600 mg/d for 10 days) was used as a calibrator </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 486 patients with a left ventricular ejection fraction â‰¤40% and at least 1 ICD intervention for <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> or <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> in the previous month or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation in the previous month for documented <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>/<z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> were randomized </plain></SENT>
<SENT sid="5" pm="."><plain>Median treatment duration was 9 months </plain></SENT>
<SENT sid="6" pm="."><plain>The primary efficacy end point was occurrence of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>/<z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo>-triggered <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> interventions (shocks or antitachycardia pacing) or <z:hpo ids='HP_0001699'>sudden death</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The proportion of patients experiencing an appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> intervention or <z:hpo ids='HP_0001699'>sudden death</z:hpo> was 61.5% in the placebo group; 67.0%, 58.8%, and 54.9% in the celivarone 50-, 100-, and 300-mg groups, respectively; and 45.3% in the <z:chebi fb="0" ids="2663">amiodarone</z:chebi> group </plain></SENT>
<SENT sid="8" pm="."><plain>Hazard ratios versus placebo for the primary end point ranged from 0.860 for celivarone 300 mg to 1.199 for celivarone 50 mg </plain></SENT>
<SENT sid="9" pm="."><plain>None of the comparisons versus placebo were statistically significant </plain></SENT>
<SENT sid="10" pm="."><plain>Celivarone had an acceptable safety profile </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Celivarone was not effective for the prevention of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> interventions or <z:hpo ids='HP_0001699'>sudden death</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov </plain></SENT>
<SENT sid="13" pm="."><plain>Unique identifier: NCT00993382 </plain></SENT>
</text></document>